Dyadic International (DYAI) Stock Price, News & Analysis

Company Overview

Dyadic International, Inc. is a biotechnology company focused on developing and commercializing microbial protein-expression technologies for the production of biologic products. Its platforms are designed to enable the efficient development and manufacture of proteins used in vaccines, therapeutics, food and nutrition products, and industrial applications.

The company’s principal technology, the C1 expression platform, is based on a proprietary strain of the fungus Trichoderma reesei. Dyadic has also developed additional microbial systems, including the Dapibus platform, which is intended to support the production of proteins and other biological materials in yeast. These technologies may be used by Dyadic and its partners to develop recombinant proteins, antibodies, enzymes, antigens, and other products.

Dyadic works with pharmaceutical, biotechnology, food, and industrial organizations through research collaborations, licensing arrangements, and technology partnerships. The company serves a global market and has historically emphasized applications that could offer scalable and cost-effective alternatives to conventional mammalian-cell manufacturing. Dyadic International is headquartered in Jupiter, Florida, and was founded by Mark Emalfarb, who has served as the company’s chief executive officer.

Key Stats

• Today's Range: $0.39 to $0.41
• 50-Day Range: $0.38 to $0.74
• 52-Week Range: $0.34 to $1.60
• Volume: 19,711 shs
• Average Volume: 176,671 shs
• Market Capitalization: $15.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Dyadic International Stock Analysis - MarketRank™

Dyadic International scored higher than 16% of companies evaluated by MarketBeat, and ranked 845th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Dyadic International has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Dyadic International has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Dyadic International are expected to grow in the coming year, from ($0.15) to ($0.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dyadic International is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dyadic International is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dyadic International has a P/B Ratio of 13.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.61% of the float of Dyadic International has been sold short.

Short Interest Ratio / Days to Cover

Dyadic International has a short interest ratio ("days to cover") of 1.69, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dyadic International has recently increased by 8.76%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dyadic International does not currently pay a dividend.

Dividend Growth

Dyadic International does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Dyadic International has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Dyadic International this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dyadic International insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.90% of the stock of Dyadic International is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

27.95% of the stock of Dyadic International is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/29/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DYAI
• CIK: 1213809
• Web: www.dyadic.com
• Phone: (561) 743-8333
• Fax: 561-743-8343
• Employees: 5
• Year Founded: 1979

Profitability

• EPS (Trailing Twelve Months): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.36 million
• Net Margins: -201.43%
• Pretax Margin: -201.43%
• Return on Equity: -2,920.31%
• Return on Assets: -84.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.65
• Quick Ratio: 1.65

Sales & Book Value

• Annual Sales: $1.33 million
• Price / Sales: 11.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.03 per share
• Price / Book: 13.14

Miscellaneous

• Outstanding Shares: 40,064,000
• Free Float: 31,691,000
• Market Cap: $15.79 million
• Optionable: Optionable
• Beta: 0.96